(Q35407910)

8 August 2017

0 references

1 reference

title

Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis (English)

1 reference

8 August 2017

1 reference

1 reference

1 reference

Junjie Zhao

1

1 reference

8 August 2017

Weidong Xu

2

1 reference

8 August 2017

Zhensheng Zhang

3

1 reference

8 August 2017

Ruixiang Song

4

1 reference

8 August 2017

Shuxiong Zeng

5

1 reference

8 August 2017

Yinghao Sun

6

1 reference

8 August 2017

Chuanliang Xu

7

1 reference

8 August 2017

publication date

11 November 2014

1 reference

International Urology and Nephrology

8 August 2017

published in

1 reference

8 August 2017

volume

47

1 reference

8 August 2017

issue

1

1 reference

8 August 2017

page(s)

87-94

1 reference

8 August 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Functionalized polymeric nanoparticles loaded with indocyanine green as theranostic materials for targeted molecular near infrared fluorescence imaging and photothermal destruction of ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Prognostic Values of p53 and HER-2/neu Coexpression in Invasive Bladder Cancer in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Expression of the epidermal growth factor receptor family in normal and malignant urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

HER-2 and TOP2A coamplification in urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Bladder cancer in 2010: how far have we come?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Histologic grading of noninvasive papillary urothelial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Biomarkers in bladder cancer: translational and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0866-Z

Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer

21 January 2018

1 reference

12 December 2020

Microarray as a model for quantitative visualization chemistry.

1 reference

12 December 2020

Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

1 reference

12 December 2020

Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome

1 reference

12 December 2020

10.1007/S11255-014-0866-Z

Identifiers

DOI

1 reference

8 August 2017

1 reference